NCT00772395 - Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Bone Loss

Interventions

DRUG

Risedronate

35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)

DRUG

Placebo

Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)

Trial Locations (1)

Orthopaedic department, Danderyd Hospital, Stockholm